Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
CertaraAugust 13, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling
The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…
CertaraAugust 5, 2025
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
CertaraJuly 31, 2025
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development
Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.
CertaraJuly 29, 2025
ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered
ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…
CertaraJuly 23, 2025
MIDD can ease pediatric & rare disease drug loss in Japan
Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…
CertaraJuly 8, 2025
